Evaluation of a single-use gastroscope in patients presenting with suspected upper gastrointestinal hemorrhage: a pilot feasibility study (One-Scope I).

BACKGROUND : Outbreaks of multidrug-resistant bacteria due to contaminated duodenoscopes and infection risks during the COVID-19 pandemic have driven the development of single-use endoscopes. The first single-use gastroscope is now available in Europe. Besides waste disposal and cost issues, the infection risk and performance remain unclear. We aimed to evaluate a single-use gastroscope in patients with signs of upper gastrointestinal bleeding. METHODS : 20 consecutive patients presenting with clinical signs of upper gastrointestinal bleeding between October and November 2022 were included in this case series. The primary aim was technical success, defined as access to the descending duodenum and adequate assessment of the upper gastrointestinal tract for the presence of a bleeding site. RESULTS : The primary aim was achieved in 19/20 patients (95 %). The bleeding site was identified in 18 patients. A therapeutic intervention was performed in six patients (two cap-mounted clips, one standard hemostatic clip, two variceal band ligations, one hemostatic powder, two adrenaline injections); technical and clinical success were achieved in all six patients. Two crossovers to a standard gastroscope occurred. CONCLUSIONS : Use of single-use gastroscopes may be feasible for patients presenting for urgent endoscopic evaluation and treatment of upper gastrointestinal bleeding.

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

A. Ebigbo reports consulting fees from Ambu and Olympus. H. Messmann reports relationships with Ambu, Boston Scientific, Fujifilm, Hitachi, and Olympus; has received honoraria from Olympus; and has received consultation fees from Ambu, Boston Scientific, and Olympus. V. Tadic, J. Schlottmann, G. Braun, F. Prinz, J. Wanzl, M. Ayoub, L. Kraus, M. Scheppach, S. Nagl, E. Schnoy, T. Weber, A. Probst, and C. Römmele declare that they have no conflict of interest.